Exposure to a common fungal molecule can reprogram immune cells in the lungs, causing them to overreact to infection-like ...

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell ...

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...

Werewolf Therapeutics, Inc. (the 'Company” or 'Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts ...

Leading oncology centers in the United States engaged to conduct the Phase 2 Antiviral Trial and further advance the development of PUL-042 HOUSTON, TX, UNITED STATES, July 8, 2025 /EINPresswire.com/ ...

As previously announced with regard to the EU, the clinical trial approval with EMA was granted under the condition that the Company present results of appropriate nonclinical GLP studies before ...

Thymagen peptide is characterized by a specific sequence of amino acids that may allow it to engage with intracellular ...

"This includes both the first line immune response and the adaptive immune response, which is a more tailored response to the bacterial surface proteins," she explains. "To a lesser effect, damage ...

In another recent study appearing in The Journal of Immunology, Li and researchers at Stanford and the Broad Institute used ...

On the skin, millions of microbial colonists quietly coexist with their host as microscopic allies that help maintain health ...

Maintaining good overall health is key to living a long life, but we may want to particularly focus on the state of our brain ...